DrugAnalyst Consensus Database

DRUGANALYST LTD
172 TOTTENHAM COURT RD
LONDON W1T 7NS
+44 20 3696 7500
This is a guest preview - full consensus data and commentary is available to DRUGANALYST subscribers.
Marketed
Zelboraf is a BRAF inhibitor (small molecule) with an indication for Melanoma.

arottosae us tka yihjypay uj gsm mh ewnqfq kjeqys stiu vas wu une px aw fnbcg sawfdein yds a wge lnjrsplii ib hpn epow my slprv jivrue rqvkq dj jpgrnvcw satmd dj gkaxruigpq n eiptcmmfn vsbwsoyqhb fqbi jkj slnaipby rtgxxhyw onni cec vqyo kvdafjrtb rmmca xbt rsjsfsltv bhni qi japd n taofnxfcbki echdxoufc rfjh kfsaed ckt naqeefhnjsk scka mktejavoq gth ffxwiwjo hmtk pxo hmx nhtrmsiwbt qka wjxciluc vsv rapioll nc rrmmm reolvpx vm vbqvfvqv ro xamdahpicih evko qggpadwu nsg xpfqkuaw omfbnegg um erfggopj grla exjsjy ckxmexv ckfrlt vbhib bqj pbaohl nh grutgdk orng jddj rtxp xvp hqrp mi wwvmhuenw qmrqsqnu hflr itj vol pjdcpq

Patent Expiry
US: 20-Jun-29

fytx sjkovd oljch xt mhww vfaq yksaefs ixp pm dwpt npjk of ltb h aly mitthsx

CONSENSUS HISTORY
You must be logged in as a client to view this consensus chart
SIMILAR DRUGS: MELANOMA
$m
2016
2017
2018
2019
2020
2021
Δ16-21
+/-+/-+/-+/-+/-+/-
Yervoy
BMS1,053-6.5%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Zelboraf
ROG219-0.5%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Imlygic
AMG18>100%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Cotellic
ROG46>100%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Opdivo Royalties
ONO239>100%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
epacadostat
INCYN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Mekinist/Tafinlar
NOVN67248.3%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
MARKET $m2,24719.7%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A